Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B
暂无分享,去创建一个
[1] L. Graf. Extended Half-Life Factor VIII and Factor IX Preparations , 2018, Transfusion Medicine and Hemotherapy.
[2] F. Peyvandi,et al. First‐year results of an expanded humanitarian aid programme for haemophilia in resource‐constrained countries , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.
[3] J. Puetz,et al. Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.
[4] J. Mahlangu,et al. Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.
[5] P. Monahan,et al. Safety and efficacy of investigator‐prescribed BeneFIX® prophylaxis in children less than 6 years of age with severe haemophilia B , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.
[6] Alan R. Cohen,et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.
[7] C. Kessler. New perspectives in hemophilia treatment. , 2005, Hematology. American Society of Hematology. Education Program.
[8] M. Manco‐Johnson. Update on treatment regimens: prophylaxis versus on-demand therapy. , 2003, Seminars in hematology.
[9] J. Katz. Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large‐scale North American survey , 1996, Haemophilia : the official journal of the World Federation of Hemophilia.
[10] H. Pettersson,et al. Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.